[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"community-acquired-pneumonia-cap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:community-acquired-pneumonia-cap":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,44,70,102,131,159,187,209,232,263,297,323,349,378,406,426],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100054133","lefamulin-post-market-surveillance-study-100054133",false,"NCT07697885","Lefamulin Post-Market Surveillance Study","A Multicenter, Single-arm, Real-world Study to Evaluate the Safety and Efficacy of Lefamulin in Patients With Community-acquired Pneumonia","Inclusion Criteria:\n\n1. Signed informed consent form\n2. Clinical diagnosis of community-acquired pneumonia (CAP) by treating physicians\n3. Currently receiving lefamulin treatment or prescribed and agreed to initiate lefamulin therapy as determined by the treating physician\n\nExclusion Criteria:\n\n1. Patients with contraindications to lefamulin according to the approved prescribing information (e.g., known hypersensitivity to lefamulin or pleuromutilin class antibiotics)\n2. Pulmonary infiltrates caused by non-infectious factors (e.g., pulmonary embolism, aspiration chemical pneumonitis, hypersensitivity pneumonitis, congestive heart failure, bronchial obstruction, lung cancer, cystic fibrosis)\n3. Confirmed or suspected empyema via chest X-ray or CT examination\n4. Participation in any other ongoing interventional clinical trial","ALL",{"count":18,"type":19},1000,"ESTIMATED","1 Month","OBSERVATIONAL","Community-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually. Elderly CAP patients carry a higher mortality risk. The predominant pathogens of CAP in China are Mycoplasma pneumoniae and Streptococcus pneumoniae, followed by Haemophilus influenzae, Staphylococcus aureus and other pathogens.\n\nCommonly used antibacterial agents include macrolides, penicillins, cephalosporins, respiratory quinolones and tetracyclines. Nevertheless, drug resistance is prevalent nationwide. Specifically, the resistance rate of Mycoplasma pneumoniae to macrolides ranges from 54.9% to 71.7%, while that of Streptococcus pneumoniae reaches as high as 77.2% to 93.8%. Therefore, novel antibacterial agents covering common pathogens with low cross-resistance are urgently needed.\n\nLefamulin is the first systemic pleuromutilin antibacterial agent for human use. It binds to the peptidyl transferase center of bacterial 50S ribosomal subunit via dual A\u002FP sites to inhibit bacterial protein synthesis. It features low cross-resistance and low potential to induce drug resistance, and exerts broad-spectrum antibacterial activity against common typical and atypical pathogens (including multi-drug resistant strains) causing CAP.\n\nMultiple Phase III randomized controlled trials have verified that lefamulin achieves favorable early clinical response (ECR) and investigator-assessed clinical response (IACR) in CAP patients, providing solid evidence-based support for its clinical application. As a safer and more effective therapeutic option for CAP, lefamulin has been recommended by domestic and international clinical guidelines and expert consensus.\n\nThis study aims to evaluate the safety and efficacy of lefamulin in real-world clinical treatment among Chinese patients with CAP.",[24],"Community-Acquired Pneumonia (CAP)",[26,27,28,29,30,31],"lefamulin","post-marketing","real-world study","community-acquired bacterial pneumonia","antibiotic","pleuromutilin","NOT_YET_RECRUITING","2026-07-06",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":19},"2026-06-30",{"date":40,"type":19},"2028-12-31",{"name":42,"class":43},"Marubeni Pharmaceuticals (Suzhou) Co., Ltd.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100638770","multimodal-assisted-diagnosis-for-pediatric-respiratory-diseases-using-questionnaires-cough-sounds-and-breath-sounds-100638770","NCT07613242","Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Questionnaires, Cough Sounds, and Breath Sounds","A Prospective Observational Study of Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Symptom Questionnaires, Cough Sounds, and Breath Sounds","Inclusion Criteria:\n\nChildren aged 28 days to 18 years, regardless of sex, will be eligible for inclusion. The disease group will include children presenting to the outpatient department, emergency department, or inpatient wards of Shanghai Children's Medical Center with cough, wheezing, fever with respiratory symptoms, nasal congestion, rhinorrhea, sore throat, or other respiratory complaints. Participants should be able to complete the symptom questionnaire, cough sound recording, and breath sound recording, and their guardians must provide informed consent and allow review of relevant medical history and diagnostic information. The healthy control group will include children recruited from routine health examinations or children without respiratory complaints, with no acute respiratory symptoms within the past 4 weeks, no known history of chronic respiratory diseases, no obvious respiratory abnormalities on health assessment or research team review, the ability to complete relevant data collection, and guardian informed consent.\n\nExclusion Criteria:\n\nParticipants will be excluded if they have severe cardiopulmonary malformations, long-term tracheostomy or mechanical ventilation, severe neuromuscular disorders, severe immunodeficiency, or other conditions that may substantially alter cough sound characteristics or affect the clinical presentation of respiratory diseases. Children whose primary diagnosis at the current visit is a non-respiratory disease and who are not suitable for this study will also be excluded. Participants who are unable to complete the symptom questionnaire, or whose cough sound or breath sound recordings remain of insufficient quality after repeated attempts, will not be included or will be excluded from the corresponding modality-specific analysis. Participants with only one unavailable modality may be included in analyses based on the completed modalities but will be excluded from analyses requiring the missing modality. Healthy controls will be excluded from the main control analysis if recent respiratory symptoms, a history of chronic respiratory disease, or other conditions that may affect acoustic features are identified.",true,"28 Days","18 Years",{"count":55,"type":19},1400,"This study aims to establish a standardized, synchronized data collection system for pediatric symptom questionnaires, cough sounds, and breath sounds, and to construct a multimodal database of pediatric respiratory diseases including both disease cases and healthy controls. Using the final research labels determined by clinicians' diagnoses, health status assessments, and research team review as the reference standard, this study will develop and validate a multimodal assisted diagnostic model for common pediatric respiratory diseases based on symptom questionnaires, cough sounds, and breath sounds. The study will primarily evaluate the diagnostic performance of the model in distinguishing healthy children from children with respiratory diseases, screening for asthma and asthma-related cough, and identifying pneumonia, tracheitis\u002Fbronchitis, upper airway-related diseases, and common causes of chronic cough. It will also assess the incremental value of cough sounds and breath sounds beyond symptom questionnaire information.",[58,24],"Asthma (Diagnosis)","2026-05-23",{"date":61,"type":36},"2026-05-29",{"date":63,"type":19},"2026-06-01",{"date":65,"type":19},"2029-05-31",{"name":67,"class":68},"Shanghai Children's Medical Center","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":69},"100570656","phase-3-targeting-vascular-inflammation-in-patients-with-community-acquired-pneumonia-100570656","NCT06710080","Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia","Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial","TIN-CAP","Inclusion Criteria:\n\nPatients who have:\n\n1. Hospitalization with CAP (defined as pulmonary infiltration using chest imaging, in addition to other clinical symptoms including fever, cough, and sputum)\n2. age \\> 18 years;\n3. given informed consent.\n\nExclusion Criteria:\n\nPatients who have:\n\n1. history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix).\n2. active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate));\n3. pregnancy (all women of child bearing potential will have a negative BHCG test;\n4. breastfeeding;\n5. Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception.\n6. Allergies to icosapent ethyl\n7. allergies to fish or shellfish\n8. glomerular filtration rate (GFR) \\\u003C50 ml\u002Fmin\u002F1.72m2 (excluded from CTA portion)\n9. unable to give informed consent;\n\nExclusion for CTA portion of the protocol:\n\nPatients with dye allergy will not undergo CTA but will have PET\u002FCT",{"count":79,"type":19},168,"INTERVENTIONAL",[82],"PHASE3","The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is:\n\nWhat is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP.\n\nParticipants wil:\n\n* take Vacscepa or a placebo twice a day for 6 months\n* Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests",[85,86,87],"Inflammation","Community Acquired Pneumonia (CAP)","Inflammation Plaque, Atherosclerotic",[89,90,85,91],"Community-Acquired Infection","Plaque, atherosclerotic","Eicosapentaenoic Acid","RECRUITING","2026-05-08",{"date":95,"type":36},"2026-05-11",{"date":97,"type":36},"2026-04-08",{"date":99,"type":19},"2027-06",{"name":101,"class":68},"Ottawa Heart Institute Research Corporation",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":80,"phases":111,"briefSummary":113,"conditions":114,"keywords":119,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":69},"100640645","phase-2-multicenter-phase-ii-trial-of-nricm102-combined-with-standard-therapy-in-pneumonia-100640645","NCT07583992","Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia","Inclusion Criteria:\n\n1. Male or female subjects aged 18 to 85 years\n2. The subjects are diagnosed with community-acquired pneumonia (CAP) at the time of hospital admission and must meet all of the following criteria:\n\n   Chest X-ray showing new onset or persistent pulmonary infiltrate At least two of the following abnormal clinical or laboratory findings: (a) Cough, (b) Sputum production, (c) Fever (≥37.8℃) or hypothermia (\\\u003C35℃), (d) Auscultatory findings of rales or bronchial breath sounds, (e) White blood cell count greater than 10×10⁹\u002FL or less than 4×10⁹\u002FL\n3. Subjects requiring hospitalization and intravenous antibiotic therapy\n4. Subjects who have received standard antibiotic therapy for less than 24 hours after hospital admission\n5. Subjects who are able to take the investigational product orally\n6. Subjects who are able to understand and comply with all study procedures and provide written informed consent\n\nExclusion Criteria:\n\n1. Subjects who have received systemic antibiotic treatment within 72 hours prior to screening; routine antibiotics administered after hospital admission are not included in this restriction\n2. Subjects who have used oral traditional Chinese medicine (TCM) or traditional Chinese medicine preparations that may affect efficacy assessment within 7 days prior to hospital admission\n3. Subjects who have been hospitalized within 15 days prior to current admission\n4. Subjects with aspiration pneumonia\n5. Subjects requiring admission to the intensive care unit (ICU)\n6. Subjects requiring hemodialysis\n7. Subjects with any malignancy, except those who have completed curative treatment with no signs of recurrence for more than five years and require no further anticancer therapy (based on medical history)\n8. Subjects with human immunodeficiency virus (HIV) infection\n9. Subjects requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), steroids, or other immunosuppressants\n10. Subjects requiring antiviral agents for COVID-19 infection or influenza\n11. Subjects must be on a stable dose of Omeprazole or Warfarin\n12. Subjects with alcohol or substance abuse, or other major organic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, tuberculosis (TB), or significant heart, kidney, or other major organ dysfunction or failure (based on medical history)\n13. Female subjects who are pregnant, breastfeeding, or of childbearing potential, or those intending to become pregnant between the signing of the Informed Consent Form (ICF) and the final observation\u002Fstudy time point, or who are unwilling to use an appropriate method of contraception. Acceptable highly effective methods of contraception include:\n\n    1. Surgical sterilization (male or female), contraceptive implants, or intrauterine devices (IUDs).\n    2. Injectable contraceptives, oral contraceptives, contraceptive patches, or vaginal rings, used in combination with one barrier method.\\*\n    3. Combination of two barrier methods.\\* \\*Effective barrier methods include diaphragms, male or female condoms, contraceptive sponges, or spermicides (creams or gels containing spermicidal chemicals).\n14. Subjects deemed unsuitable for study participation by the investigator","85 Years",{"count":110,"type":19},150,[112],"PHASE2","The goal of this clinical trial is to learn if NRICM102 (a Traditional Chinese Medicine) works to treat community-acquired pneumonia (CAP) in adults when added to standard antibiotic therapy. It will also learn about the safety of NRICM102. The main questions it aims to answer are:\n\n1. Does NRICM102 help participants reach clinical stability faster compared to placebo?\n2. What medical problems do participants have when taking NRICM102?\n\nResearchers will compare NRICM102 to a placebo (a look-alike substance that contains no drug) to see if NRICM102 works as an add-on treatment for community-acquired pneumonia.\n\nParticipants will:\n\n1. Take NRICM102 or a placebo (2 sachets, 3 times daily) in addition to standard intravenous antibiotic treatment for 7 days\n2. Be hospitalized and visited by the study team on Day 1, Day 4, and Day 8 for vital sign monitoring, symptom assessments, laboratory tests, and chest X-ray examinations\n3. Be contacted by telephone on Day 30 to check if they were readmitted to the hospital after discharge",[115,24,116,117,118],"Mild to Moderate","Antibiotic Therapy","Intravenous","Hospitalisation",[120,24,121],"NRICM102","National Research Institute of Chinese Medicine, Ministry of Health and Welfare","2026-05-07",{"date":124,"type":36},"2026-05-13",{"date":126,"type":19},"2026-06",{"date":128,"type":19},"2027-11",{"name":121,"class":130},"OTHER_GOV",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":139,"maxAge":53,"enrollmentInfo":140,"targetDuration":4,"studyType":80,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100600629","promoting-optimal-treatment-for-community-acquired-pneumonia-in-emergency-rooms-100600629","NCT07099976","PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms","PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms (PIONEERS): a Multicentre, Randomized, Open-labelled, Controlled, Clinical Trial","PIONEERS","Inclusion Criteria:\n\nChildren aged 6 month to 18 years presenting to the Emergency Department who are diagnosed with CAP and are well enough to be discharged home (i.e. 'non-severe' CAP) will be eligible. They must have a fever (on exam or by history) and at least one of:\n\n* Tachypnoea measured at triage (\\>60 bpm for age \\\u003C1, \\>50 for 1-2 years of age, \\>40bpm for 2-4 years of age, and \\>30bpm for \\>4 years of age)\n* Cough on exam or by history\n* Increased work of breathing on exam\n* Auscultatory finding (focal crackles, bronchial breathing, etc.) consistent with CAP\n\nExclusion Criteria:\n\nChildren will be excluded if they have any of the following\n\n* Cystic Fibrosis\n* Anatomic Lung Disease\n* Bronchiectasis\n* Chronic Lung Disease requiring home oxygen or home ventilation\n* Congenital heart Disease (requiring specific medical treatment or with exercise restrictions),\n* History of repeated aspiration\u002Fvelopharyngeal incompetence\n* Malignancy\n* Immunodeficiency (primary, acquired or iatrogenic)\n* Pneumonia previously (clinically) diagnosed within the past month (that was presumed to have resolved prior to the episode prompting the current visit to the ED)\n* Lung abscess within the past 6 months\n* Children who present with ongoing fever after 4 days of amoxicillin, cefprozil, cefuroxime, levofloxacin, moxifloxacin or doxycycline are not eligible; as this duration of therapy with these drugs would normally be sufficient to treat bacterial CAP, a different approach would be required (ie. the care pathway as written might not be appropriate).\n* Children will not be eligible to participate more than once","6 Months",{"count":141,"type":19},698,[143],"NA","In North America, up to 5% of preschoolers develop community-acquired pneumonia (CAP) every year. Pneumonia is the second-leading reason for paediatric hospitalization in both Canada and the US; approximately 20% of children hospitalized with CAP may need intensive care, which can result in significant morbidity. Given this burden of disease, it is critical that CAP is managed appropriately. Specific therapy for CAP is dependent on microbiologic aetiology, as bacterial disease will improve with antibiotic treatment.",[24,146],"Pneumonia",[146,148],"Antibiotics","2026-04-23",{"date":151,"type":36},"2026-04-29",{"date":153,"type":36},"2026-04-15",{"date":155,"type":19},"2030-05-15",{"name":157,"class":68},"Jeffrey Pernica",6,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":80,"phases":169,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100634263","phase-4-ceftriaxone-dosage-for-non-critical-community-acquired-pneumonia-100634263","NCT07537413","Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia","Pragmatic Randomized Trial Evaluating Dosage of Ceftriaxone for Community-Acquired Pneumonia Outside the Intensive Care Unit","DC-CAP","Inclusion Criteria:\n\n* Evaluated in the emergency department or within 72 hours of hospitalization\n* Prescribed Ceftriaxone for community-acquired pneumonia\n\nExclusion Criteria:\n\n* Planned or present admission to an intensive care unit\n* Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula",{"count":168,"type":19},430,[170],"PHASE4","Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.\\\u003Cp\\>\n\nHypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.",[86],[174,175,176],"community acquired pneumonia","ceftriaxone","antibiotic dosing","2026-04-16",{"date":179,"type":36},"2026-04-17",{"date":181,"type":19},"2026-09-01",{"date":183,"type":19},"2028-02-28",{"name":185,"class":68},"University of Maryland, Baltimore",2,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":80,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":208},"100584657","phase-4-comparing-hydrocortisone-and-prednisolone-for-community-acquired-pneumonia-cap-100584657","NCT06892197","Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of severe CAP for who the physician in charge decides for corticosteroid therapy for severe CAP.\n\nExclusion Criteria:\n\n* Admitted \\>24 h\n* Pregnant or breastfeeding women\n* Active tuberculosis or fungal infection\n* Pneumonia caused by influenza\n* Intolerance to either study drug",{"count":194,"type":19},1600,[170],"The goal of this cluster randomized controlled trial is to determine the optimal treatment for community aquired pneumonia (CAP). The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 18 years old diagnosed with severe CAP. The main question is whether there is a difference in all cause mortality within thirty days.\n\nParticipants will be randomized to receive treatment with either hydrocortisone or prednisolone.",[86],"2026-03-16",{"date":200,"type":36},"2026-03-18",{"date":202,"type":36},"2026-03-10",{"date":204,"type":19},"2030-11-01",{"name":206,"class":207},"Copenhagen Respiratory Research","NETWORK",14,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":80,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":69},"100629241","effect-of-tngs-on-cap-patients-with-initial-treatment-failure-100629241","NCT07472114","Effect of tNGS on CAP Patients With Initial Treatment Failure","Impact of Targeted Next-generation Sequencing on Hospitalized Patients With Community-acquired Pneumonia and Initial Treatment Failure","Inclusion Criteria:\n\n* Adults (age ≥ 18 years)\n* Diagnosed of community-acquired pneumonia\n* Initial treatment failure\n\nExclusion Criteria:\n\n* tNGS or mNGS already performed on respiratory samples during the current illness\n* Suspected lung abscess or empyema\n* Cerebral infarction within the past three months\n* Dysphagia\n* Nasopharyngeal carcinoma currently receiving radiotherapy\n* Tracheostomy\n* Long-term bedridden patients (ADL score ≤ 60)\n* Pathogens identified within the past 7 days that adequately explain the current clinical presentation\n* Bronchiectasis with large amounts of sputum and documented bacterial detection within the past six months\n* Inability to obtain eligible respiratory samples\n* CURB-65 score ≤ 1\n* Expected discharge or death within 48 hours",{"count":217,"type":19},524,[143],"This is a multicenter, randomized controlled trial designed to evaluate the impact of tNGS in patients with community-acquired pneumonia who experience initial treatment failure.",[86],[222,174,223,224],"targeted next generation sequencing","RCT","initial treatment failure","2026-03-12",{"date":198,"type":36},{"date":228,"type":19},"2026-04-10",{"date":183,"type":19},{"name":231,"class":68},"Capital Medical University",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":240,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":80,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100591878","comparing-antibiotic-treatment-strategies-for-children-with-pneumonia-in-outpatient-settings-stampp-100591878","NCT06986148","Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)","Comparing Antibiotic Treatment Strategies for Children With Community-Acquired Pneumonia in Outpatient Settings (Safety-Net Antibiotic Prescribing to Manage Pediatric Pneumonia [STAMPP])","STAMPP","Inclusion Criteria:\n\n* Aims 1 and 2:\n* Presenting with signs and symptoms of lower respiratory tract infection\n* Diagnosed with community-acquired pneumonia (CAP) by a clinician\n* The treating clinician intends to prescribe antibiotics for CAP, AND\n* Well enough, as determined by the clinician at the time of the study enrollment visit, to be managed as an outpatient.\n* Aim 3:\n* Parent\u002Fguardian of child enrolled in the trial, OR\n* Clinician who makes prescribing decision at the study site, OR\n* Other practice-based parties (e.g. nurses, pharmacists, medical assistants, practice leaders) at study sites who can comment on the implementation of each prescribing strategy.\n\nExclusion Criteria:\n\n* Aims 1 and 2:\n* Hospitalization within the previous 7 days\n* Oxygen saturation below 90%, if measured\n* Incomplete immunization status (e.g., lacking at least 3 doses of the pneumococcal vaccines, typically given as part of the 2-, 4-, and 6-month vaccinations)\n* Chronic medical conditions that increase the risk of bacterial CAP (e.g., chronic lung disease, cystic fibrosis, sickle cell disease),\n* Substantially immunocompromised status (e.g., immunodeficiency, active cancer treatment, organ transplant with concurrent immunosuppressive agents)\n* Receipt of oral or parenteral antibiotics within the previous 7 days\n* Diagnosis of complicated pneumonia (e.g., empyema, lung abscess)\n* Known bacterial source of infection warranting immediate antibiotics\n* Pneumonia diagnosis within the previous 6 months, OR\n* Prior enrollment in the trial\n* Inability of the parent or guardian to speak English or Spanish\n* Aim 3:\n* Inability of the parent or guardian to speak English","12 Months","71 Months",{"count":243,"type":19},2000,[143],"The goal of this clinical trial is to determine if a \"watch and wait\" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are:\n\n* To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP)\n* To identify which patient groups benefit most from the SNAP strategy\n* To identify factors that shape implementation of each prescribing strategy.\n\nResearchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other.\n\nParticipants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.",[86,247],"Community Acquired Pneumonia",[249,250,146,251,252],"Community-acquired Pneumonia","Pediatric Respiratory Diseases","Antibiotic Use","SNAP","2026-01-24",{"date":255,"type":36},"2026-01-27",{"date":257,"type":36},"2025-09-09",{"date":259,"type":19},"2029-07-16",{"name":261,"class":68},"Ann & Robert H Lurie Children's Hospital of Chicago",4,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":80,"phases":273,"briefSummary":274,"conditions":275,"keywords":286,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":295,"locationsCount":69},"100620566","impact-of-a-multimodal-intervention-on-antibiotic-prescribing-for-respiratory-infections-in-primary-care-100620566","NCT07359287","Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care","Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care: A Cluster-Randomized Trial","GRASP","Inclusion Criteria:\n\n\\- Patient seen in consultation for an upper or lower respiratory tract infection (Angina, Acute bronchiolitis, Acute bronchitis, COPD exacerbation (AECOPD), Laryngitis, Acute otitis media (AOM), Serous or congestive otitis, Viral respiratory infection (e.g., influenza), Community-acquired pneumonia (CAP), Rhinitis \u002F Nasopharyngitis, Acute sinusitis)\n\nExclusion Criteria:\n\n\\- Patient under legal protection",{"count":272,"type":19},4500,[143],"Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France are prescribed and where misuse remains common.\n\nWe are proposing a cluster-randomized controlled trial to evaluate the effectiveness of a bimodal intervention combining: (1) improved communication about the circulation of respiratory viruses, and (2) strengthened collaborative practices between general practitioners and pharmacists through a multidisciplinary protocol aimed at verifying that prescribed treatment durations comply with guidelines.\n\nThe study will include six primary care practices (24 physicians), with three practices in each study arm.\n\nThe aim of this project is to assess whether the bimodal intervention can reduce the duration of antibiotic treatments for upper and lower respiratory tract infections. The first component (a \"viral infection prescription\" tool) focuses on reducing unnecessary treatment initiation, while the second (pharmacist-led review) aims to shorten excessive prescription durations.",[276,277,278,279,280,281,282,283,24,284,285],"Angina","Acute Bronchiolitis","Acute Bronchitis","COPD Exacerbation (AECOPD)","Laryngitis","Acute Otitis Media (AOM)","Serous or Congestive Otitis","Viral Respiratory Infection (e.g., Influenza)","Rhinitis \u002F Nasopharyngitis","Acute Sinusitis",[287,288],"Upper respiratory tract infection","Lower respiratory tract infection","2026-01-13",{"date":291,"type":36},"2026-01-22",{"date":293,"type":36},"2025-12-01",{"date":181,"type":19},{"name":296,"class":68},"University Hospital, Caen",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":69},"100574171","italian-registry-of-pneumonia-in-immunocompromised-patients-argonaut-100574171","NCT06755814","ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)","Community-acquired Pneumonia in Immunosuppressed Adult Patients: Observational, Perspective Study, ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)","ARGONAUT","Inclusion Criteria:\n\nHospitalized patients with a confirmed diagnosis of Community-Acquired Pneumonia (CAP) characterized by at least one of the following risk factors for immunosuppression:\n\n* AIDS,\n* Aplastic anemia;\n* Asplenia;\n* Hematologic malignancy (e.g., lymphoma\u002Facute or chronic myeloid leukemia\u002Fmultiple myeloma);\n* Chemotherapy within the last 3 months;\n* Neutropenia defined as a white blood cell count less than 500\u002FdL on a complete blood count;\n* Use of biologics (including trastuzumab and therapy for autoimmune diseases (e.g., anti-TNF α), prescribed within the last 6 months before hospital admission;\n* Solid organ transplant;\n* Bone marrow transplant;\n* Chronic oral steroid use (\\>10 mg\u002Fday prednisone or equivalent ≥3 months before accessing the ED, or cumulative dose \\> 600 mg prednisone);\n* Use of corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent ≥14 days or cumulative dose \\> 600 mg prednisone;\n* Active malignancy;\n* Malignancy within one year of pneumonia (excluding patients with localized skin cancer or early-stage malignancy);\n* Lung malignancy with neutropenia\u002Fchemotherapy;\n* Other solid malignancy with neutropenia\u002Fchemotherapy;\n* Other immunodeficiency (including congenital\u002Fgenetic immunosuppression and immunosuppressive therapy secondary to hematologic malignancy or solid malignancy);\n* Primary immunodeficiency.\n\nExclusion Criteria:\n\n* None",{"count":306,"type":19},1298,"This multicentric, prospective study aims at:\n\nevaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical, microbiological and genetic analysis on collected samples.",[86],[310,311,312,146,313],"CAP","Immunosuppressed","Immunocompromised","community-acquired pneumonia;","2025-11-14",{"date":316,"type":36},"2025-11-18",{"date":318,"type":36},"2025-08-11",{"date":320,"type":19},"2028-12",{"name":322,"class":68},"Societa Italiana di Pneumologia",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":80,"phases":332,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":69},"100567531","phase-1-opt101-in-patients-with-community-acquired-pneumonia-cap-with-sepsis-100567531","NCT06669403","OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis","A Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis","Inclusion Criteria:\n\n1. Are able and willing to give signed informed consent (legally authorized representative can provide informed consent if needed).\n2. ≥18 years old;\n3. Patients hospitalized for clinically suspected community acquired pneumonia (CAP), defined as the occurrence of (within 48h from hospital admission) at least 1 of the following signs:\n\n   * respiratory rate \\> 30 breaths\u002Fmin;\n   * fever (\\> 38.0°C or \\> 100.4° F);\n   * leukopenia (≤ 4,000 WBC\u002Fmm3 or leukocytosis (≥ 12,000 WBC\u002Fmm3);\n   * adults ≥ 70 years of age; altered mental status with no other recognized cause;\n\n   AND at least 1 of the following:\n   * New onset of purulent sputum or change in character of sputum or increased respiratory secretions;\n   * New onset or worsening cough, or dyspnea, or tachypnea;\n   * Rales or bronchial breath sounds; AND Radiologic imaging (chest x-ray or CT scan) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation AND SpO2 \\\u003C92% at room air, or PaO2\u002FFiO2 (or SpO2\u002FFiO2) \\\u003C300; recorded on one episode\n4. Need for non-invasive supplemental oxygen (nasal cannula, simple mask, venturi or reservoir cannula\u002Fmask or heated high flow nasal cannula oxygen.\n5. Females of child-bearing potential who are sexually active must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:\n\n   * Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last OPT101 dose\n   * A non-hormonal intrauterine device \\[IUD\\] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last OPT101 dose\n   * A male sexual partner who agrees to use a male condom with spermicide\n   * A sterile sexual partner\n\nExclusion Criteria:\n\n1. Need for endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at time of study screening\n2. QTc ≥ 450 msec on screening ECG\n3. Hepatic dysfunction: ALT or AST \\> 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score ≥ 12)\n4. Recent or active hepatitis A infection; test positive or have been treated for hepatitis B, hepatitis C, or HIV infection; evidence of active or untreated latent TB; a recent history of recurrent herpes zoster and\u002For opportunistic infection; and\u002For taking immunosuppressant medication.\n5. Renal dysfunction: estimated glomerular filtration rate (eGFR) \\\u003C50 mL\u002Fmin\u002F1.73 m2, or need for hemodialysis or hemofiltration\n6. Current use of \\>2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC \\\u003C local LLN), solid organ or bone marrow transplant recipients)\n7. Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period\n8. Anticipated discharge from the hospital or transfer to another hospital within 48 hours of screening\n9. Allergy to OPT101or any component of OPT101 formulation\n10. Participation in other interventional clinical trials\n11. Pregnancy:\n\n    * positive or missing pregnancy test before first drug intake or day 1\n    * pregnant or lactating women;\n    * Women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study\n12. Current hospital stay \\>72h\n13. Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism\n14. Weight is over 250lbs\n15. Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study. The Principal Investigator should make this determination in consideration of the patient's medical history and current clinical condition.\n\n    \\-",{"count":331,"type":19},26,[333],"PHASE1","OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis.\n\nThis study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.",[336,86],"Sepsis",[336,86,338,339,340],"Immunomodulator","OPT101","Op-T LLC","2025-09-08",{"date":343,"type":36},"2025-09-15",{"date":345,"type":19},"2025-12",{"date":347,"type":19},"2026-05",{"name":340,"class":43},{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":80,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":4},"100582141","phase-2-local-antibiotic-delivery-for-community-acquired-pneumonia-100582141","NCT06859450","Local Antibiotic Delivery for Community Acquired Pneumonia","Local Antibiotic Delivery for Community Acquired Pneumonia - Pilot Study (LANDCAP1)","LANDCAP-1","Inclusion Criteria:\n\n1. Hospital admission within 24 hours.\n2. Radiologically new-onset chest infiltrate that is consistent with pneumonia and symptoms or signs also consistent with pneumonia, such as fever, cough, sputum, dyspnoea and\u002For chest pain\n3. CURB-65 score 3-5\n4. C-reactive protein \\>50 OR central body temperature \\>38.0 °C (1-2 of these fulfilled)\n5. Age ≥ 18 years\n6. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Septic shock according to the sepsis III criteria:41 sequential organ failure assessment (SOFA) score ≥2) and suspected infection (according to attending physician) and persisting hypotension requiring vasopressors to maintain MAP≥65 mmHg and serum lactate level\\>2 mmol\u002FL (18 mg\u002FdL) despite adequate volume resuscitation (30 mL\u002Fkg crystalloid within 3 hours).\n2. Oxygen requirement ≥5 L\u002Fmin to maintain acceptable saturation assessed by the treating physician.\n3. Respiratory rate \\>24\u002Fmin with relevant oxygen therapy\n4. Positive COVID or influenza test (PCR or antigen test)\n5. Known allergy to levofloxacin or other fluoroquinolones or a serious adverse reaction when previously treated with a fluoroquinolone, including tendinitis or tendon-rupture related to fluoroquinolone treatment\n6. Symptoms of neuropathy (peripheral paraesthesia, hypoesthesia, or hyperalgesia)\n7. Known allergy to β-lactam antibiotics or to macrolide antibiotics.\n8. Medical history of myasthenia gravis\n9. Reduced kidney function (eGFR \\\u003C 20)\n10. Expected transfer to ICU or death within 48 hours or a do not resuscitate ordination at time of recruitment.\n11. Suspected aspiration pneumonia, pulmonary abscess, or pleural empyema \u002F complicated parapneumonic effusion.\n12. Clinically significant cardiac conduction disorders\u002Farrhythmias or prolonged QTc interval (QTc (f) \\> 480ms).\n13. Pregnancy (a negative pregnancy test is required prior to inclusion of all pre-menopausal women)",{"count":358,"type":19},36,[112,82],"A randomized, double-blinded clinical pilot study to assess whether addition of inhaled levofloxacin 240 mg twice daily for three days leads to improved or worsened physiological status in CAP patients with and without pre-existing lung disease.",[86],[247,363,364,365,366,367,368,369],"Inhaled levofloxacin","Inhaled antibiotics","feasibility","Chronic obstructive pulmonary disease","asthma","pulmonary healthy","pilot study","2025-03-05",{"date":372,"type":36},"2025-03-10",{"date":374,"type":19},"2025-03-04",{"date":376,"type":19},"2028-09-01",{"name":206,"class":207},{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":16,"minAge":385,"maxAge":386,"enrollmentInfo":387,"targetDuration":4,"studyType":80,"phases":389,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":4},"100573518","clinical-trial-of-fei-re-qing-granules-in-the-treatment-of-elderly-community-acquired-pneumonia-100573518","NCT06747325","Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia","Inclusion Criteria:\n\n* Inpatients diagnosed with community-acquired pneumonia (CAP) according to the diagnostic criteria.\n* Diagnosed with Phlegm-Heat Obstructing the Lungs syndrome based on Traditional Chinese Medicine (TCM).\n* Aged ≥65 and ≤80 years, regardless of gender.\n* Onset of illness within 72 hours.\n* Clinical symptoms must include at least two of the following four primary。symptoms: cough, sputum production, dyspnea, and pleuritic chest pain.\n* Voluntary participation and signed informed consent.\n\nExclusion Criteria:\n\n* Patients with altered mental status, consciousness disorders, dementia, or psychiatric disorders.\n* Patients requiring invasive mechanical ventilation or endotracheal intubation.\n* Patients with conditions such as pleural effusion, bronchiectasis, active pulmonary tuberculosis, pulmonary abscess, lung cancer, asthma, or chronic obstructive pulmonary disease (COPD).\n* Patients with neuromuscular diseases or those bedridden for long periods, posing a risk of aspiration.\n* Patients with cancer, severe cardiovascular diseases (acute myocardial infarction, heart failure stage III or above), or severe liver and kidney diseases (e.g., cirrhosis, portal hypertension with variceal bleeding, dialysis, or kidney transplantation).\n* Patients participating in other drug clinical trials or known to be allergic to the study medication.","65 Years","80 Years",{"count":388,"type":19},120,[143],"This study aims to evaluate the clinical efficacy of traditional Chinese medicine formula granules (Fei Re Qing Granules) in the treatment of elderly community-acquired pneumonia, establish a treatment protocol, and obtain high-level clinical evidence.",[24],[393,394,395,396],"elderly community-acquired pneumonia (CAP)","traditional Chinese medicine","randomized controlled trial","Fei Re Qing Granules","2024-12-18",{"date":399,"type":36},"2024-12-24",{"date":401,"type":19},"2025-01-01",{"date":403,"type":19},"2025-06-01",{"name":405,"class":68},"Henan University of Traditional Chinese Medicine",{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":4},"100571119","clinical-characteristics-and-outcome-of-patients-with-community-acquired-pneumonia-100571119","NCT06716099","Clinical Characteristics and Outcome of Patients With Community Acquired Pneumonia","Inclusion Criteria:\n\n* The study will include patients ≥18 years old with community acquired pneumonia\n\nExclusion Criteria:\n\n1. Patients already was diagnosed as active malignancy before admission\n2. Patient on chemotherapy\n3. HIV patients\n4. Indication of mechanical ventilation on admission",{"count":413,"type":19},100,"the goal of this observational study is to evaluate the clinical characteristic and outcomes of patients with community-acquired pneumonia admitted to Sohag University Hospital.\n\nthe researcher will take medical history and clinical examination and investigations of participants .\n\nthe participants will visit the clinic after one month to be reevaluated again .",[86],[310,146,417],"clinical characteristics","2024-11-29",{"date":420,"type":36},"2024-12-04",{"date":422,"type":19},"2024-12-15",{"date":345,"type":19},{"name":425,"class":68},"Sohag University",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":80,"phases":435,"briefSummary":436,"conditions":437,"keywords":438,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":448,"leadSponsor":450,"locationsCount":69},"100562606","clinical-impact-of-rapid-molecular-testing-for-pathogens-in-patients-with-severe-acute-respiratory-illness--a-pragmatic-trial-100562606","NCT06605352","Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial","CIRT-RMT-SARI","Inclusion Criteria:\n\n1. Admitted to the ED\n2. Age ≥18 years old\n3. Diagnosis of SARI -modified from the World Health Organization definition:\n\n   * history of fever or measured fever of ≥ 38 C° and cough\n   * with onset within the last 10 days.\n   * requires hospitalization.\n   * with SpO2 on presentation less than 95% or respiratory rate more than 20 per minute, or requirement of intubation and mechanical ventilation.\n\nExclusion Criteria:\n\n1. Patients receiving palliative care\n2. Patients who declined sample collection\n3. Patients fail to provide written informed consent.\n4. Patients highly suspected or diagnosed pulmonary non-infectious disease (tumor, immune disease, etc) without evidence of infection.\n5. Patients diagnosed with COVID-19 within last 3 months.\n6. HIV-infected patients.\n7. Off work hour collected samples will be excluded from the study.\n8. Patients who died or being transitioned to comfort care within 48 hours of enrollment.\n\nStudy Population Description Inclusion criteria will be 1) ED patients age 18 or older; 2) presenting to the emergency department with acute severe respiratory illness. We define a case of severe acute respiratory illness (SARI) according to a previously suggested WHO case definition for all adults in whom onset of illness occurred within 7 days of admission. We defined SARI in adult as physician-diagnosed lower respiratory tract infection (LRTI) with SpO2 on presentation less than 95% or respiratory rate more than 20 per minute, or requirement of intubation and mechanical ventilation.\n\nSampling Method: random sampling",{"count":434,"type":19},800,[143],"Community-acquired pneumonia (CAP) is among the most common reasons for emergency department (ED) visits. A clear understanding of the likely pathogens is essential for the rapid institution of adequate antimicrobial therapy. Due to the indistinguishable clinical symptoms between viral and bacterial pathogens, patients with viral respiratory infection are usually under-evaluated while unnecessary antibacterial agents are more likely to be administered. With the development of highly sensitive end-to-end point-of-care (POC) multiplex PCR system, rapid diagnosis of respiratory pathogens for CAP in the ED becomes possible. Our previous NTUH-VGH cooperative research project demonstrated POC respiratory viral testing' in conjunction with procalcitonin test can reduce the length of hospital stay and antibiotic consumption. However, viral testing alone cannot guide precision antimicrobial treatment. A complete pneumonia pathogen testing panel should include bacteria, virus, atypical pathogens, and resistant genes. In addition, such test need to be completed within about time at a reasonable cost. The difficult missing has been recently achieved. The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18 bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes. Currently, the world is eagerly to learn how this new diagnostic technology can transform the clinical management of pneumonia. With this in mind, the aim of this study is to evaluate the impact of POC pneumonia pathognome wide testing on the antimicrobial use and outcome of patients. We will perform an open label pragmatic parallel comparison between patients with\u002Fwithout the test. The results will inform the pneumonia guideline. Subsequent health economic analysis based on this study will be important to the reimbursement policy of the health insurance of Taiwan.",[24,146],[439,440,441,146,442,443],"Community-acquired pneumonia (CAP)","multiplex PCR","emergency department (ED)","Procalcitonin(PCT)","antimicrobial resistance","2024-09-18",{"date":446,"type":36},"2024-09-20",{"date":446,"type":19},{"date":449,"type":19},"2026-12",{"name":451,"class":68},"National Taiwan University Clinical Trial Center"]